| Literature DB >> 34194822 |
Yu-Fang Huang1, Kai-Li Liang2, Chiao-Ying Liang1, Po-Chin Yang3, Jun-Peng Chen4, Li-Chen Wei1.
Abstract
BACKGROUNDS: Acute invasive fungal rhinosinusitis (AIFRS) is a hazardous infectious disease with rapid progression and high mortality and morbidities. Further orbital involvement is commonly seen. This study aims to analyze risk factors, clinical characteristics, and outcomes between patients with or without orbital involvement.Entities:
Year: 2021 PMID: 34194822 PMCID: PMC8214473 DOI: 10.1155/2021/9987871
Source DB: PubMed Journal: J Ophthalmol ISSN: 2090-004X Impact factor: 1.909
Figure 1This was a 73-year-old male patient. He died 22 days after disease onset. The culture reported Rhizopus. (a) The patient presented as left facial swelling and tenderness, left eye proptosis, painful extraocular movement, eyelid swelling and erythema, conjunctival injection and chemosis, and cornea edema. (b) Computed tomography revealed orbital intraconal infiltration, extraocular muscles swelling, and sinusitis over maxillary and ethmoid sinuses. (c) Magnetic resonance imaging was performed 2 days after the CT, which revealed ipsilateral brain edema with midline shift.
Figure 2This was a 67-year-old female patient. Her pathological diagnosis was Mucor spp. She died 26 days after admission. (a) She presented as right eye blurry vision, limited extraocular movement, conjunctival injection and chemosis, and mild proptosis. (b) Computed tomography revealed orbital infiltration and subperiosteal abscess. Fluid accumulation over the frontal, ethmoid, and maxillary sinuses was seen. (c) Magnetic resonance imaging showed ipsilateral brain edema over the temporal region. This was taken 18 days after the CT image (b).
Comparison of patients' characteristics, symptoms and signs, culture reports, and image findings between the orbital-involved and sparing group in patients diagnosed with AIFRS (DM: diabetes mellitus; EOM: extraocular movement).
| Orbital involvement ( | Orbital sparing ( | Total ( |
| |
|---|---|---|---|---|
|
| ||||
| Male | 6 (66.7%) | 7 (58.3%) | 13 (61.9%) | 1.000 |
| Age, years† | 64.0 (56.5–71.5) | 55.0 (37.5–67.8) | 58.0 (47.0–69.5) | 0.109 |
| Onset days† | 14.0 (8.5–17.0) | 13.0 (2.8–19.3) | 14.0 (6.5–18.5) | 0.668 |
|
| ||||
|
| ||||
| DM | 9 (100.0%) | 2 (16.7%) | 10 (47.6%) | <0.001 |
| Hypertension | 7 (77.8%) | 1 (8.3%) | 7 (33.3%) | 0.002 |
| Renal insufficiency | 4 (44.4%) | 0 (0.0%) | 4 (19.0%) | 0.021 |
| Systemic steroid use | 1 (11.1%) | 1 (8.3%) | 2 (9.5%) | 1.000 |
| Malignancy solid tumor | 0 (0.0%) | 2 (16.7%) | 2 (9.5%) | 0.486 |
| Malignancy hematology | 1 (11.1%) | 8 (66.7%) | 9 (42.9%) | 0.024 |
|
| ||||
|
| ||||
| Nasal obstruction | 1 (11.1%) | 4 (33.3%) | 5 (23.8%) | 0.338 |
| Nasal discharge | 4 (44.4%) | 3 (25.0%) | 7 (33.3%) | 0.397 |
| Cheek pain | 4 (44.4%) | 4 (33.3%) | 8 (38.1%) | 0.673 |
| Facial swelling | 1 (11.1%) | 2 (16.7%) | 3 (14.3%) | 1.000 |
| Ptosis | 4 (44.4%) | 1 (8.3%) | 5 (23.8%) | 0.119 |
| Orbital pain | 6 (66.7%) | 2 (16.7%) | 8 (38.1%) | 0.032 |
| Orbital swelling | 4 (44.4%) | 1 (8.3%) | 5 (23.8%) | 0.119 |
| Decreased visual acuity | 8 (88.9%) | 0 (0.0%) | 8 (40.0%) | <0.001 |
| EOM limitation | 7 (77.8%) | 0 (0.0%) | 7 (35.0%) | <0.001 |
| Fever | 3 (33.3%) | 12 (100.0%) | 15 (71.4%) | 0.002 |
| Headache | 4 (44.4%) | 1 (8.3%) | 5 (23.8%) | 0.119 |
| Conscious disturbance | 5 (55.6%) | 1 (8.3%) | 6 (28.6%) | 0.046 |
|
| ||||
|
| ||||
| | 2 (22.2%) | 1 (8.3%) | 3 (14.3%) | 0.553 |
| | 1 (11.1%) | 0 (0.0%) | 1 (4.8%) | 0.429 |
| | 4 (44.4%) | 1 (8.3%) | 5 (23.8%) | 0.119 |
| | 3 (33.3%) | 9 (75.0%) | 12 (57.1%) | 0.087 |
| | 0 (0.0%) | 1 (8.3%) | 1 (4.8%) | 1.000 |
|
| ||||
|
| ||||
| Frontal sinus | 6 (66.7%) | 1 (8.3%) | 7 (33.3%) | 0.016 |
| Ethmoid sinus | 9 (100.0%) | 4 (33.3%) | 13 (61.9%) | 0.005 |
| Sphenoid sinus | 8 (88.9%) | 2 (16.7%) | 10 (47.6%) | 0.002 |
| Maxillary sinus | 8 (88.9%) | 8 (66.7%) | 16 (76.2%) | 0.338 |
Chi-square test or Fisher's exact test. Mann–Whitney U test, median (IQR). p < 0.05, p < 0.01.
The comorbidities, symptoms and signs, and image findings of alive or expired patients with fungal orbital infection related to AIFRS (DM: diabetes mellitus; EOM: extraocular movement).
| Alive ( | Dead ( |
| |
|---|---|---|---|
|
| |||
| Male | 3 (75.0%) | 3 (60.0%) | 1.000 |
| Age, years | 62.0 (48.0–73.0) | 67.0 (56.5–71.5) | 0.806 |
| Onset days | 10.5 (7.0–14.0) | 14.0 (11.0–20.5) | 0.211 |
|
| |||
|
| |||
| DM | 4 (100.0%) | 5 (100.0%) | — |
| Hypertension | 2 (50.0%) | 5 (100.0%) | 0.167 |
| Renal insufficiency | 2 (50.0%) | 2 (40.0%) | 1.000 |
| Malignancy hematology | 0 (0.0%) | 1 (20.0%) | 1.000 |
| Malignancy solid tumor | 0 (0.0%) | 0 (0.0%) | — |
| Systemic steroid use | 1 (25.0%) | 0 (0.0%) | 0.444 |
| HbA1C (%) | 10.7 (9.28–13.98) | 10.0 (8.0–14.0) | 0.480 |
|
| |||
|
| |||
| Fever | 1 (25.0%) | 3 (60.0%) | 0.524 |
| Headache | 2 (50.0%) | 2 (40.0%) | 1.000 |
| Nasal obstruction | 1 (25.0%) | 0 (0.0%) | 0.444 |
| Nasal discharge | 2 (50.0%) | 2 (40.0%) | 1.000 |
| Cheek pain | 2 (50.0%) | 3 (60.0%) | 1.000 |
| Facial swelling | 0 (0.0%) | 1 (20.0%) | 1.000 |
| Orbital pain | 2 (50.0%) | 4 (80.0%) | 0.524 |
| Orbital swelling | 1 (25.0%) | 3 (60.0%) | 0.524 |
| Ptosis | 1 (25.0%) | 3 (60.0%) | 0.524 |
| Decreased visual acuity | 3 (75.0%) | 5 (100.0%) | 0.444 |
| EOM limitation | 3 (75.0%) | 4 (80.0%) | 1.000 |
| Conscious disturbance | 0 (0.0%) | 5 (100.0%) | 0.008 |
|
| |||
|
| |||
| Orbital subperiosteal abscess | 1 (25.0%) | 4 (80.0%) | 0.206 |
| Orbital intraconal infiltration | 3 (75.0%) | 5 (100.0%) | 0.444 |
| Extraocular muscles swelling | 2 (50.0%) | 4 (80.0%) | 0.524 |
| Optic nerve swelling | 1 (25.0%) | 3 (60.0%) | 0.524 |
| Encephalitis (brain edema and brain abscess) | 0 (0.0%) | 3 (60.0%) | 0.167 |
Fisher's exact test. p < 0.01.